The Career Development Program is designed to increase the translational investigator base in the Mayo Myeloma SPORE by identifying and fostering the early careers of young investigators who have an interest in multiple myeloma translational research. In particular, this program provides much-needed support for promising young laboratory or clinical investigators early in their careers so that they can focus their energies on research projects related to multiple myeloma research. We have requested $50,000 in this application to support this program. Mayo, as part of its commitment through the Mayo Comprehensive Cancer Center, has agreed to match these funds. Thus, we would plan to commit a total of $100,000 to the career development program. The Career Development Program makes maximal use of the scientific expertise within the Mayo community. The Career Development Program Committee is responsible for organizing the program and reviewing research proposals as submitted.

Public Health Relevance

The purpose of this program is to support and mentor young investigators at the junior faculty level so that they can become outstanding translational investigators with a primary focus on multiple myeloma. Each individual selected for the project is provided 2 years of salary support ($50,000 per year). Each awardee is expected to spend the 2 years engaged in multiple myeloma translational research under the aegis of a suitable mentor. Again, support for only one of these individuals is being requested by the grant. Developmental funds from the Mayo Comprehensive Cancer Center will.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Arizona
United States
Zip Code
Baughn, Linda B; Pearce, Kathryn; Larson, Dirk et al. (2018) Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer J 8:96
Russell, Stephen J; Barber, Glen N (2018) Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines. Cancer Cell 33:599-605
Clay-Gilmour, Alyssa I; Kumar, Shaji; Rajkumar, S Vincent et al. (2018) Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. Leukemia :
Sidiqi, M Hasib; Aljama, Mohammed A; Muchtar, Eli et al. (2018) Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Adv 2:769-776
Nair, Shiny; Sng, Joel; Boddupalli, Chandra Sekhar et al. (2018) Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 3:
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Go, Ronald S; Rajkumar, S Vincent (2018) How I manage monoclonal gammopathy of undetermined significance. Blood 131:163-173
Kyle, Robert A; Larson, Dirk R; McPhail, Ellen D et al. (2018) Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clin Proc 93:739-746
Calcinotto, Arianna; Brevi, Arianna; Chesi, Marta et al. (2018) Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat Commun 9:4832
Facon, Thierry; Dimopoulos, Meletios A; Dispenzieri, Angela et al. (2018) Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131:301-310

Showing the most recent 10 out of 95 publications